DaVita shares plunge 17% on August 5 despite Q2 earnings beat

What happened

DaVita Inc. (NYSE: DVA) stock fell 17.24% on August 5, 2026, to close at $188.69, after the kidney dialysis provider reported Q2 2026 results on August 4 that beat analyst estimates. According to Yahoo Finance, the volume was 3.8 million shares, 4.6 times the average. The decline occurred despite adjusted EPS of $4.02 (above the ~$3.88 consensus) and revenue of $3.554 billion, according to DaVita's official press release.

Analysts and financial media attributed the drop to a sequential decline in U.S. dialysis revenue per treatment (to $415.87, down $1.72 from Q1), a weaker commercial payer mix, elevated costs and margin pressure, and the company reaffirming rather than raising its full-year 2026 adjusted EPS guidance of $14.10–$15.20. Tickeron noted that disappointing full-year guidance (midpoint below some expectations) and profit-taking after a ~100% year-to-date rally also contributed.

The filing

In its Q2 2026 earnings release, DaVita reported operating income of $579 million (16.3% margin). The company maintained its full-year 2026 adjusted EPS guidance at $14.10–$15.20 and adjusted operating income guidance at $2.15–$2.25 billion. The sequential drop in revenue per treatment was attributed to lower commercial mix, the expiration of ACA subsidies, and the impact of phosphate binders, according to Tickeron's analysis.

The official press release did not explain the stock price movement, which is standard for earnings filings.

Market reaction

Shares of DaVita dropped sharply in pre-market trading on August 5, with the decline accelerating through the session, resulting in a 17.24% loss on heavy volume. According to Zacks via Yahoo Finance, the stock fell despite the earnings beat due to margin compression and revenue-per-treatment pressure. The company's decision to hold guidance steady disappointed investors who had expected an upward revision after a strong year-to-date performance, as noted by Tickeron.